Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats

British Journal of Pharmacology

Volumn 136, Issue 8, 2002, Pages 1107-1116

  Haverdings, R Folgert G ^a   Haas, Marijke ^a   Navis, Gerjan ^a   Van Loenen Weemaes, Anne Miek ^a   Meijer, Dirk K F ^a   De Zeeuw, Dick ^a   Moolenaar, Frits ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

ACE inhibitor; Blood pressure; Captopril lysozyme; Natriuresis; Proteinuria; Renal ACE inhibition; Renal drug targeting; Renal haemodynamics

Indexed keywords

ANGIOTENSIN I; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; DRUG CARRIER; LYSOZYME;

ANIMAL; ARTICLE; BLOOD FLOW; BLOOD PRESSURE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYMOLOGY; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MALE; NEPHROTIC SYNDROME; RAT; RETRACTED ARTICLE; VASCULARIZATION; WISTAR RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; KIDNEY BLOOD FLOW; NATRIURESIS; NONHUMAN; PRESSOR RESPONSE; PRIORITY JOURNAL;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CAPTOPRIL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; KIDNEY; MALE; MURAMIDASE; NEPHROTIC SYNDROME; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW;

EID: 0036686585     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704814     Document Type: Article

References (56)

1. Role of local and systemic angiotensin in diabetic renal disease
2. Quantification of conversion and degradation of circulating angiotensin in rats
3. Renal responses of the nonclipped kidney of two-kidney/one-clip Goldblatt hypertensive rats to type 1 angiotensin II receptor blockade with candesartan
4. Comparison of renal hemodynamic effect of ramiprilat to captopril; possible role of kinins
5. Megalin and cubilin: Synergistic endocytic receptors in renal proximal tubule
6. Structural and functional features of protein handling in the kidney proximal tubule
7. Angiotensin I- to II-conversion in the human vascular bed
8. A method for accurate measurement of GFR in conscious, spontaneously voiding rats
9. Molecular basis of renal fibrosis
10. Progression and potential regression of glomerulosclerosis
11. Dietary Na and ACE inhibition on renal tissue angiotensin I and II and ACE activity in rats
12. Renal specific delivery of sulfamethoxazole in the rat by coupling to the low molecular weight protein lysozyme via an acid-sensitive linker
13. Low molecular weight proteins as carriers for renal drug targeting: Naproxen coupled to lysozyme via the spacer L-lactic acid
14. Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosis
15. Delivery of drugs and antisense oligonucleotides to the proximal tubular cell of the kidney using macromolecular and prodrug approaches
16. Drug-targeting to the kidney: Renal delivery and degradation of a naproxen-lysozyme conjugate in vivo
17. Renal drug targeting: Optimization of renal pharmaco-therapeutics
18. Control of glomerular filtration rate by circulating angiotensin II
19. Drug targeting to the kidney: 'The low-molecular-weight protein approach'
20. Heterogeneity of angiotensin action in renal circulation
21. Control of glomerular filtration rate: Role of intrarenally formed angiotensin II
22. Effect of intrarenal angiotensin II blockade on renal function in conscious dogs
23. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme
24. Bioanalysis of captopril: Two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling
25. Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: Role of kinins
26. Control of renal function by intrarenal angiotensin II in the dog
27. Control of renal function by intrarenal angiotensin II
28. Demonstration of a primary antidiuretic action of angiotensin II: Effects of intrarenal converting enzyme inhibition in the conscious dog
29. Responses of blood pressure and angiotensin-converting enzyme activity to acute captopril administration in normotensive and hypertensive rats
30. Renal protective effects of blocking the intrarenal renin-angiotensin system
31. Relation between inhibition of renal angiotensin II production and hemodynamic effect of captopril in anaesthetized rabbit
32. Intrarenal converting enzyme inhibition in rabbit
33. Renal medullary captopril delivery lowers blood pressure in spontaneously hypertensive rats
34. Renal filtration, transport, and metabolism of proteins
35. Angiotensin-converting enzyme in non-neoplastic kidney diseases
36. Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in low-renin hypertension
37. Concentrations and actions of intraluminal angiotensin II
38. Paracrine regulation of the renal microcirculation
39. Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats
40. The renal tubule in the progression of chronic renal failure
41. Comparison of systemic and direct intrarenal angiotensin II blockade on sodium excretion in rats
42. Analysis of influence of extra- and intrarenally formed angiotensin II on renal blood flow
43. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats
44. ACE inhibitors and AT(1) receptor antagonists-beyond the haemodynamic effect
45. Combined intrarenal blockade of the renin-angiotensin system in the conscious dog
46. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect
47. Renoprotective benefits of RAS inhibition. From ACEI to angiotensin II antagonists
48. Effect of intrarenal renin inhibition on renal hemodynamic and excretory function
49. Circulatory and extracirculatory effects of angiotensin-converting enzyme inhibition
50. An accurate and rapid method for the determination of protein in small amounts of blood, serum and plasma
51. Preventing renal disease progression: Is it the drug or the blood pressure reduction, or both?
52. Assay of tissue angiotensin converting enzyme
53. Role of extrarenal and intrarenal converting enzyme inhibition in renal vasodilator response to intravenous captopril
54. Drug protein conjugates-VI. Role of glutathione in the metabolism of captopril and captopril plasma protein conjugates
55. Comparison of systemic and intrarenal converting enzyme inhibition by MK-422 on renal hemodynamics in conscious dogs
56. No effect of intrarenal converting enzyme inhibition on canine renal blood flow